Insider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Sells 25,687 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 25,687 shares of the firm’s stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $22.66, for a total value of $582,067.42. Following the completion of the transaction, the chief financial officer now owns 189,242 shares of the company’s stock, valued at approximately $4,288,223.72. This represents a 11.95 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, March 11th, Troy Wichterman sold 4,151 shares of BioLife Solutions stock. The shares were sold at an average price of $25.00, for a total transaction of $103,775.00.
• On Monday, March 3rd, Troy Wichterman sold 660 shares of BioLife Solutions stock. The stock was sold at an average price of $25.46, for a total value of $16,803.60.
• On Wednesday, February 12th, Troy Wichterman sold 159 shares of BioLife Solutions stock. The shares were sold at an average price of $26.54, for a total value of $4,219.86.
• On Monday, January 6th, Troy Wichterman sold 987 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total transaction of $26,668.74.

BioLife Solutions Trading Down 5.6 %

BLFS stock traded down $1.34 during trading on Thursday, reaching $22.44. The company had a trading volume of 591,144 shares, compared to its average volume of 358,590. BioLife Solutions, Inc. has a 52 week low of $14.84 and a 52 week high of $29.55. The company has a market cap of $1.05 billion, a P/E ratio of -21.17 and a beta of 2.04. The business has a 50 day moving average of $26.11 and a 200 day moving average of $25.54. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The firm had revenue of $22.71 million for the quarter, compared to analysts’ expectations of $21.73 million. During the same period in the previous year, the firm posted ($0.21) EPS. As a group, sell-side analysts forecast that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on BLFS shares. StockNews.com lowered BioLife Solutions from a “hold” rating to a “sell” rating in a research note on Monday. Northland Securities increased their price objective on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research note on Wednesday, January 8th. Benchmark reaffirmed a “buy” rating and issued a $30.00 target price on shares of BioLife Solutions in a research note on Thursday, December 19th. HC Wainwright upped their price target on shares of BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, March 6th. Finally, KeyCorp boosted their price objective on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.86.

Institutional Investors Weigh In On BioLife Solutions

Institutional investors and hedge funds have recently made changes to their positions in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of BioLife Solutions by 13.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,686 shares of the medical equipment provider’s stock worth $1,835,000 after acquiring an additional 8,258 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in BioLife Solutions during the fourth quarter valued at $31,000. Point72 Asset Management L.P. bought a new position in shares of BioLife Solutions in the 4th quarter worth approximately $11,113,000. ProShare Advisors LLC purchased a new position in shares of BioLife Solutions during the 4th quarter worth $282,000. Finally, Millennium Management LLC grew its stake in shares of BioLife Solutions by 49.1% during the 4th quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider’s stock valued at $29,733,000 after acquiring an additional 377,111 shares during the period. Institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.